Immuno Cure's HIV/AIDS Vaccine ICVAX Wins Big, Attracts RMB 60M Investment
Immuno Cure BioTech, a Hong Kong-based biotech company, has made waves in the industry with its HIV/AIDS therapeutic DNA vaccine, ICVAX. The company recently won the Grand Prize at the National Final of the 1st GBA Entrepreneurship Competition, attracting significant investment and praise for its innovative technology.
ICVAX, based on patented technology from the University of Hong Kong's AIDS Institute, has shown promising results in Phase I clinical trials. The vaccine demonstrated excellent safety and immunogenicity profiles, paving the way for upcoming Phase II trials. This rapid progress has been attributed to the expertise of the Immuno Cure team and the global potential of the project.
The company's success was further cemented when ICVAX was selected as the Champion in the Biomedical and Bio-manufacturing Track of the Competition. This prestigious award was one of many highlights, with over 30% of finalists hailing from Hong Kong and Macao, reflecting the region's thriving biotech scene.
Immuno Cure's achievements have not gone unnoticed by investors. The company attracted an expression of interest for RMB 60 million investment from a major mainland investment fund, further bolstering its financial strength.
With ICVAX's successful Phase I trials and upcoming Phase II trials, Immuno Cure is poised for significant growth. The company plans to apply for Breakthrough Therapy Designation upon meeting Phase II trial endpoints, aiming for commercialization in 2028. As Dr. Percy CHENG, MH, Chairman of Immuno Cure, expressed, the company is committed to developing more innovative technologies, solidifying its position as a leader in the biotech industry.
